Middle East and Africa Virology Market Trends and Analysis by 2028

The virology market in MEA is expected to grow from US$ 182.40 million in 2021 to US$ 221.46 million by 2028; it is estimated to grow at a CAGR of 2.8% from 2021 to 2028.

Economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries like Syria, Libya, and Yemen are suffering violent conflict and cannot implement any public health measures. Iran was in a deep economic recession due to the US sanctions. Additionally, tightened financial condition is also decreasing the economic activities in the region. COVID-19 is the second coronavirus outbreak that has affected the Middle East, following the MERS-CoV reported in Saudi Arabia in 2012. Many countries are facing a shortage of testing kits in the region. Considering this, many government organizations are coming forward to help countries with a lack of resources. For instance, in September, The United Nations Children’s Fund (UNICEF) delivered around 115,800 Covid-19 test kits to help mitigate the Covid-19 pandemic in Nigeria. Also, the countries in the region are collaborating with international players to increase the testing capacity. In addition, the substantial direct health, and economic impacts of the Ebola epidemic in Guinea, Liberia, and Sierra Leone, diverted basic health care and government services to the outbreak, resulting in serious under-provision of health and social care. Economic growth also slowed significantly due to reduced financial investments and productivity levels during and after the outbreak. As per the Global Fund Organization, across 24 countries in Africa, only 11% of health facilities could conduct COVID-19 antigen rapid diagnostic tests, and only 8% could conduct PCR tests. Before the COVID-19, Lassa Fever was the priority, with the annual incidence of around 300,000-500,000 cases of Lassa Fever, with 5,000 related deaths in West Africa. However, COVID-19 has diverted all the rescores in handling the pandemic has impeded the growth of the other virus infections.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive virology market. The MEA virology market is expected to grow at a good CAGR during the forecast period.

MEA Virology Market Segmentation

MEA Virology Market – By Type

• Diagnostic Test
  • DNA Virus Testing
  • RNA Virus Testing
  • Others
• Viral Infection Controlling Techniques
  • Active Prophylaxis
  • Passive Prophylaxis
• Antiviral Therapeutics
  • Virucidal Agents
  • Antiviral Agents
  • Immunomodulators
• Interferons

MEA Virology Market – By Application

• Skin and Soft Tissue Infections
• Respiratory Tract Infections
• GI Tract Infections
• Sexually Transmitted Diseases
• Urinary Tract Infections
• Others

MEA Virology Market – By End User

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical and Biotechnological Companies
• Research and Academic Institutes

MEA Virology Market- By Country

• UAE
• Saudi Arabia
• South Africa
• Rest of MEA

MEA Virology Market-Companies Mentioned

• Abbott
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• Illumina, Inc.
• Johnson and Johnson Services, Inc.
• QIAGEN
• Siemens AG
• Thermo Fisher Scientific Inc.

Middle East and Africa Virology Report Scope